# CME Group Inc.: financial statements, quarterly

CME · Nasdaq · CIK 1156375 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cme.md) · [Financials](/companies/cme/financials.md) · [Filings](/companies/cme/filings.md) · [Insiders](/companies/cme/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cme/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,439 d](/filings/0001156375-26-000009.md) | [1,488](/filings/0001156375-25-000103.md) | [1,533](/filings/0001156375-25-000182.md) | [1,584](/filings/0001156375-25-000206.md) | [1,525 d](/filings/0001156375-26-000009.md) | [1,642](/filings/0001156375-26-000020.md) | [1,692](/filings/0001156375-26-000047.md) | [1,538](/filings/0001156375-26-000068.md) | [1,649 d](/filings/0001156375-26-000009.md) | [1,880](/filings/0001156375-26-000020.md) | [1,706](/filings/0001156375-26-000047.md) | [1,737](/filings/0001156375-26-000068.md) |
| Operating income | $m | [863 d](/filings/0001156375-26-000009.md) | [960](/filings/0001156375-25-000103.md) | [1,001](/filings/0001156375-25-000182.md) | [1,024](/filings/0001156375-25-000206.md) | [947 d](/filings/0001156375-26-000009.md) | [1,108](/filings/0001156375-26-000020.md) | [1,129](/filings/0001156375-26-000047.md) | [973](/filings/0001156375-26-000068.md) | [1,020 d](/filings/0001156375-26-000009.md) | [1,310](/filings/0001156375-26-000020.md) | [1,107](/filings/0001156375-26-000047.md) | [1,141](/filings/0001156375-26-000068.md) |
| Income tax | $m | [191 d](/filings/0001156375-26-000009.md) | [258](/filings/0001156375-25-000103.md) | [271](/filings/0001156375-25-000182.md) | [264](/filings/0001156375-25-000206.md) | [222 d](/filings/0001156375-26-000009.md) | [289](/filings/0001156375-26-000020.md) | [305](/filings/0001156375-26-000047.md) | [269](/filings/0001156375-26-000068.md) | [396 d](/filings/0001156375-26-000009.md) | [357](/filings/0001156375-26-000020.md) | [286](/filings/0001156375-26-000047.md) | [318](/filings/0001156375-26-000068.md) |
| Net income | $m | [814 d](/filings/0001156375-26-000009.md) | [855](/filings/0001156375-25-000103.md) | [883](/filings/0001156375-25-000182.md) | [913](/filings/0001156375-25-000206.md) | [875 d](/filings/0001156375-26-000009.md) | [956](/filings/0001156375-26-000020.md) | [1,025](/filings/0001156375-26-000047.md) | [908](/filings/0001156375-26-000068.md) | [1,183 d](/filings/0001156375-26-000009.md) | [1,154](/filings/0001156375-26-000020.md) | [1,042](/filings/0001156375-26-000047.md) | [1,037](/filings/0001156375-26-000068.md) |
| Diluted EPS | $ per share | not reported | [2.35](/filings/0001156375-25-000103.md) | [2.42](/filings/0001156375-25-000182.md) | [2.50](/filings/0001156375-25-000206.md) | not reported | [2.62](/filings/0001156375-26-000020.md) | [2.81](/filings/0001156375-26-000047.md) | [2.49](/filings/0001156375-26-000068.md) | not reported | [3.18](/filings/0001156375-26-000020.md) | [2.88](/filings/0001156375-26-000047.md) | [2.89](/filings/0001156375-26-000068.md) |
| Basic EPS | $ per share | not reported | [2.35](/filings/0001156375-25-000103.md) | [2.43](/filings/0001156375-25-000182.md) | [2.51](/filings/0001156375-25-000206.md) | not reported | [2.63](/filings/0001156375-26-000020.md) | [2.81](/filings/0001156375-26-000047.md) | [2.49](/filings/0001156375-26-000068.md) | not reported | [3.25](/filings/0001156375-26-000020.md) | [2.89](/filings/0001156375-26-000047.md) | [2.90](/filings/0001156375-26-000068.md) |

- Revenue: us-gaap:Revenues
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [2.9](/filings/0001156375-26-000009.md) | [1.4](/filings/0001156375-25-000103.md) | [1.8](/filings/0001156375-25-000182.md) | [2.3](/filings/0001156375-25-000206.md) | [2.9](/filings/0001156375-26-000009.md) | [1.4](/filings/0001156375-26-000020.md) | [2.0](/filings/0001156375-26-000047.md) | [2.4](/filings/0001156375-26-000068.md) | [4.4](/filings/0001156375-26-000068.md) | [2.4](/filings/0001156375-26-000020.md) | [2.1](/filings/0001156375-26-000047.md) | [2.2](/filings/0001156375-26-000068.md) |
| Current assets | $bn | [94.9](/filings/0001156375-25-000021.md) | [97.3](/filings/0001156375-24-000072.md) | [88.7](/filings/0001156375-24-000149.md) | [103](/filings/0001156375-24-000200.md) | [103](/filings/0001156375-26-000009.md) | [123](/filings/0001156375-25-000103.md) | [145](/filings/0001156375-25-000182.md) | [153](/filings/0001156375-25-000206.md) | [165](/filings/0001156375-26-000068.md) | [169](/filings/0001156375-26-000020.md) | [162](/filings/0001156375-26-000047.md) | [159](/filings/0001156375-26-000068.md) |
| Total assets | $bn | [130](/filings/0001156375-25-000021.md) | [132](/filings/0001156375-24-000072.md) | [123](/filings/0001156375-24-000149.md) | [138](/filings/0001156375-24-000200.md) | [137](/filings/0001156375-26-000009.md) | [158](/filings/0001156375-25-000103.md) | [180](/filings/0001156375-25-000182.md) | [187](/filings/0001156375-25-000206.md) | [198](/filings/0001156375-26-000068.md) | [202](/filings/0001156375-26-000020.md) | [195](/filings/0001156375-26-000047.md) | [192](/filings/0001156375-26-000068.md) |
| Current liabilities | $bn | [93.4](/filings/0001156375-25-000021.md) | [96.1](/filings/0001156375-24-000072.md) | [87.0](/filings/0001156375-24-000149.md) | [101](/filings/0001156375-24-000200.md) | [102](/filings/0001156375-26-000009.md) | [121](/filings/0001156375-25-000103.md) | [143](/filings/0001156375-25-000182.md) | [150](/filings/0001156375-25-000206.md) | [160](/filings/0001156375-26-000068.md) | [166](/filings/0001156375-26-000020.md) | [159](/filings/0001156375-26-000047.md) | [156](/filings/0001156375-26-000068.md) |
| Total liabilities | $bn | [103](/filings/0001156375-25-000021.md) | [105](/filings/0001156375-24-000072.md) | [95.7](/filings/0001156375-24-000149.md) | [110](/filings/0001156375-24-000200.md) | [111](/filings/0001156375-26-000009.md) | [131](/filings/0001156375-25-000103.md) | [152](/filings/0001156375-25-000182.md) | [159](/filings/0001156375-25-000206.md) | [170](/filings/0001156375-26-000068.md) | [175](/filings/0001156375-26-000020.md) | [168](/filings/0001156375-26-000047.md) | [166](/filings/0001156375-26-000068.md) |
| Short-term borrowings | $bn | [0.0](/filings/0001156375-25-000021.md) | [0.7](/filings/0001156375-24-000072.md) | [0.7](/filings/0001156375-24-000149.md) | [0.7](/filings/0001156375-24-000200.md) | [0.7](/filings/0001156375-26-000009.md) | [0.0](/filings/0001156375-25-000103.md) | [0.0](/filings/0001156375-25-000182.md) | [0.0](/filings/0001156375-25-000206.md) | [0.0](/filings/0001156375-26-000009.md) | not reported | not reported | not reported |
| Shareholders' equity | $bn | [26.7](/filings/0001156375-25-000021.md) | [27.2](/filings/0001156375-24-000072.md) | [27.6](/filings/0001156375-24-000149.md) | [28.2](/filings/0001156375-24-000200.md) | [26.5](/filings/0001156375-26-000068.md) | [27.0](/filings/0001156375-26-000047.md) | [27.7](/filings/0001156375-26-000068.md) | [28.2](/filings/0001156375-26-000068.md) | [28.7](/filings/0001156375-26-000068.md) | [26.6](/filings/0001156375-26-000047.md) | [26.5](/filings/0001156375-26-000068.md) | [26.6](/filings/0001156375-26-000068.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,044 d](/filings/0001156375-26-000009.md) | [893](/filings/0001156375-25-000103.md) | [777 d](/filings/0001156375-25-000182.md) | [1,003 d](/filings/0001156375-25-000206.md) | [1,018 d](/filings/0001156375-26-000009.md) | [1,117](/filings/0001156375-26-000020.md) | [1,059 d](/filings/0001156375-26-000047.md) | [968 d](/filings/0001156375-26-000068.md) | [1,134 d](/filings/0001156375-26-000009.md) | [1,260](/filings/0001156375-26-000020.md) | [947 d](/filings/0001156375-26-000047.md) | [1,086 d](/filings/0001156375-26-000068.md) |
| Capital expenditure | $m | [20.8 d](/filings/0001156375-26-000009.md) | [19.8](/filings/0001156375-25-000103.md) | [18.2 d](/filings/0001156375-25-000182.md) | [29.8 d](/filings/0001156375-25-000206.md) | [26.2 d](/filings/0001156375-26-000009.md) | [14.2](/filings/0001156375-26-000020.md) | [18.4 d](/filings/0001156375-26-000047.md) | [18.4 d](/filings/0001156375-26-000068.md) | [32.5 d](/filings/0001156375-26-000009.md) | [21.8](/filings/0001156375-26-000020.md) | [23.6 d](/filings/0001156375-26-000047.md) | [15.8 d](/filings/0001156375-26-000068.md) |
| Dividends paid | $m | [400 d](/filings/0001156375-26-000009.md) | [2,328](/filings/0001156375-25-000103.md) | [419 d](/filings/0001156375-25-000182.md) | [419 d](/filings/0001156375-25-000206.md) | [419 d](/filings/0001156375-26-000009.md) | [2,567](/filings/0001156375-26-000020.md) | [455 d](/filings/0001156375-26-000047.md) | [455 d](/filings/0001156375-26-000068.md) | [455 d](/filings/0001156375-26-000009.md) | [2,698](/filings/0001156375-26-000020.md) | [468 d](/filings/0001156375-26-000047.md) | [465 d](/filings/0001156375-26-000068.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [359](/filings/0001156375-24-000072.md) | [359](/filings/0001156375-24-000149.md) | [360](/filings/0001156375-24-000200.md) | [360](/filings/0001156375-25-000103.md) | [360](/filings/0001156375-25-000182.md) | [360](/filings/0001156375-25-000206.md) | [360](/filings/0001156375-26-000020.md) | [360](/filings/0001156375-26-000047.md) | [360](/filings/0001156375-26-000068.md) | [363](/filings/0001156375-26-000020.md) | [361](/filings/0001156375-26-000047.md) | [359](/filings/0001156375-26-000068.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,643,583 at 2010-02-17, from the cover of the [10-K filed 2010-02-26](/filings/0001193125-10-043180.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.